People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2016 |
| Corner Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $95.4M | 2023 |
| Septerna, Inc. | — | Biotechnology | Series C | $73.5M | $963.7M | 2023 |
| Abide Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.2M | $83.7M | 2011 |
Alan Ezekowitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Ezekowitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Levin | 1 | 9 |
| John Clarke | 1 | 8 |
| James Collins | 1 | 8 |
| Jake Simson | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Steven Altschuler | 1 | 5 |
| Abraham Bassan | 1 | 4 |
| Jeffrey Karp | 1 | 3 |
| James Geraghty | 1 | 3 |
| Robert Gould | 1 | 3 |
| Jonathan Kagan | 1 | 3 |
| Paul Schimmel | 1 | 2 |
| Jeffrey Tong | 1 | 2 |
| Andrew Bellinger | 1 | 2 |
| Bryan Stuart | 1 | 2 |
| Richard Malley | 1 | 2 |
| Katina Dorton | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Samira Shaikhly | 1 | 1 |
| Diego Cadavid | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.